Rock inhibitor and preparation method therefor and use thereof
AssigneeWuhan Ll Science and Technology Development Co., Ltd.
InventorsJinping Li, Jun Lou, Xiaodan Guo, Xian Zeng, Yongkai Chen, Yihan Zhang, Wei Peng, Chaodong Wang
Life of this patent
Estimating the term…
Abstract
The compound represented by formula (I), and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof have ROCK inhibitory activity. The compound represented by formula (1) has good safety, good metabolic stability, and a low risk of potential hepatotoxicity. Further, the compound represented by formula (I) has a simple preparation method and is easy to purify, and therefore has good application prospects.
Claims10
A compound of formula (I) or a racemate, a stereoisomer, a tautomer, an isotopically labeled compound, a nitrogen oxide, a solvate, a polymorph, a pharmaceutically acceptable salt thereof,
- wherein,
- ring B is attached to the X via an N atom present on the ring B;
- and
- is selected from the following groups unsubstituted or optionally substituted with one, two or more Rab:
- X is —C(═O) NRx-;
- Y is methylene unsubstituted or optionally substituted with one, two or more Ry;
- ring C is the following group unsubstituted or optionally substituted with one, two or more Rc:
- phenyl, pyridinyl, pyrazolyl, imidazolyl, and benzimidazolyl;
- ring D is pyrazolyl or triazolyl unsubstituted or optionally substituted with one, two or more Rd;
- each Ry is independently H, halogen, OH, or the following group unsubstituted or optionally substituted with one, two or more R:
- methyl, ethyl, propyl, butyl, pentyl, hexyl, NH2(CH2)m—, (CH3)2N(CH2)m—, CH3NH(CH2)m—, oxetanyl, azetidinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolyl, piperidyl,
- wherein each m is independently selected from 0, 1, 2 and 3;
- wherein each R is independently ═O, halogen, CN, OH, SH, NH2, or the following group unsubstituted or optionally substituted with one, two or more R′:
- 3-7 membered heterocyclyl containing one heteroatom which is selected from nitrogen or oxygen;
- wherein each R′ is independently halogen or (C1-C6) aliphatic hydrocarbyl;
- each Rab is H, halogen, CN, or (C1-C6) aliphatic hydrocarbyl, wherein the (C1-C6) aliphatic hydrocarbyl is unsubstituted or optionally substituted with one, two or more halogen;
- each Rc is independently H, halogen, —C(O)NR11R12, or the following group unsubstituted or optionally substituted with one, two or more R:
- methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, —O(CH2)nO(CH2)mCH3, NH2(CH2)m—, (CH3)2N(CH2)m—, CH3NH(CH2)m—, —(NH)kC(O)NH2, —(NH)kC(O)NH(CH2)mCH3, —(NH)kC(O)N(CH3)(CH2)mCH3, —(NH)kC(O)(CH2)mCH3, —OC(O)(CH2)mCH3, —O(CH2)mC(═O)(CH2)m(NH)kH, or —C(O)O(CH2)mCH3, wherein each n is independently selected from 1, 2 and 3;
- each m is independently selected from 0, 1, 2 and 3;
- each k is independently selected from 0 and 1;
- wherein each R is independently ═O, halogen, CN, OH, SH, NH2, or the following group unsubstituted or optionally substituted with one, two or more R′:
- 3-7 membered heterocyclyl containing one heteroatom selected from nitrogen and oxygen, (C1-C6) aliphatic hydrocarbyl, or C3-7 alicyclic hydrocarbyl;
- wherein each R′ is independently halogen or (C1-C6) aliphatic hydrocarbyl;
- and wherein R11 is H or C3-7 alicyclic hydrocarbyl and R12 is H or C3-7 alicyclic hydrocarbyl;
- each Rd is independently H, halogen, —NH2, or (C1-C6) aliphatic hydrocarbyl, wherein the (C1-C6) aliphatic hydrocarbyl is unsubstituted or optionally substituted with one, two or more halogen;
- and
- each Rx is independently selected from H, halogen, and the following groups unsubstituted or optionally substituted with one, two or more halogen:
- methyl, ethyl, propyl, butyl, pentyl, hexyl, vinyl, propenyl, butenyl, pentenyl, hexenyl, NH2(CH2)m—, (CH3)2N(CH2)m—, CH3NH(CH2)m—, oxetanyl, azetidinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolyl, piperidyl, wherein each m is selected from 0, 1, 2, and 3.
A compound or the racemate, the stereoisomer, the tautomer, the isotopically labeled compound, the nitrogen oxide, the solvate, the polymorph, the pharmaceutically acceptable salt thereof, wherein the compound is selected from:
Dependencies are inferred from the claim text.